Amarin Corporation PLC (NASDAQ:AMRN) has been assigned a $10.00 target price by equities research analysts at Cantor Fitzgerald in a research note issued on Monday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Cantor Fitzgerald’s price objective would indicate a potential upside of 183.29% from the stock’s current price.

Several other research analysts also recently weighed in on the stock. ValuEngine raised shares of Amarin Corporation PLC from a “sell” rating to a “hold” rating in a research report on Saturday, November 4th. Zacks Investment Research downgraded shares of Amarin Corporation PLC from a “buy” rating to a “hold” rating in a research report on Friday, November 3rd. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Amarin Corporation PLC in a research report on Thursday, November 2nd. Jefferies Group LLC reissued a “buy” rating on shares of Amarin Corporation PLC in a research report on Wednesday, October 11th. Finally, BidaskClub downgraded shares of Amarin Corporation PLC from a “sell” rating to a “strong sell” rating in a research report on Thursday, August 24th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and three have given a buy rating to the company. Amarin Corporation PLC presently has an average rating of “Hold” and a consensus price target of $7.75.

Shares of Amarin Corporation PLC (NASDAQ:AMRN) traded up $0.03 on Monday, hitting $3.53. 426,400 shares of the stock traded hands, compared to its average volume of 1,764,861. The company has a debt-to-equity ratio of -1.48, a quick ratio of 1.32 and a current ratio of 1.63. Amarin Corporation PLC has a 12 month low of $2.81 and a 12 month high of $4.47.

Amarin Corporation PLC (NASDAQ:AMRN) last released its earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.01. The firm had revenue of $47.10 million during the quarter, compared to analysts’ expectations of $45.85 million. The business’s revenue was up 45.4% on a year-over-year basis. During the same period last year, the business earned ($0.08) earnings per share. research analysts forecast that Amarin Corporation PLC will post -0.22 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another website, it was copied illegally and republished in violation of United States & international copyright legislation. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/11/13/cantor-fitzgerald-analysts-give-amarin-corporation-plc-amrn-a-10-00-price-target.html.

In related news, insider Steven B. Ketchum sold 63,479 shares of the firm’s stock in a transaction that occurred on Thursday, October 5th. The shares were sold at an average price of $3.48, for a total transaction of $220,906.92. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Company insiders own 3.72% of the company’s stock.

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Westside Investment Management Inc. lifted its stake in Amarin Corporation PLC by 1.1% in the second quarter. Westside Investment Management Inc. now owns 27,350 shares of the biopharmaceutical company’s stock valued at $114,000 after acquiring an additional 300 shares during the last quarter. Wells Fargo & Company MN lifted its stake in Amarin Corporation PLC by 4.8% in the first quarter. Wells Fargo & Company MN now owns 32,801 shares of the biopharmaceutical company’s stock valued at $105,000 after acquiring an additional 1,500 shares during the last quarter. State Street Corp lifted its stake in Amarin Corporation PLC by 1.3% in the second quarter. State Street Corp now owns 201,995 shares of the biopharmaceutical company’s stock valued at $814,000 after acquiring an additional 2,640 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in Amarin Corporation PLC by 0.9% in the first quarter. Ameriprise Financial Inc. now owns 395,769 shares of the biopharmaceutical company’s stock valued at $1,266,000 after acquiring an additional 3,413 shares during the last quarter. Finally, Perkins Capital Management Inc. lifted its stake in Amarin Corporation PLC by 20.3% in the second quarter. Perkins Capital Management Inc. now owns 41,500 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 7,000 shares during the last quarter. Hedge funds and other institutional investors own 37.67% of the company’s stock.

Amarin Corporation PLC Company Profile

Amarin Corporation plc is a biopharmaceutical company with operations in lipid science focused on the commercialization and development of therapeutics for cardiovascular health. The Company operates through the development and commercialization of Vascepa segment. The Company’s lead product, Vascepa (icosapent ethyl) capsule, is approved by the United States Food and Drug Administration (FDA) for use as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia.

Receive News & Ratings for Amarin Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amarin Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.